NeuroProof

Executive Summary

NeuroProof is a German Contract Research Organization (CRO) founded in 2006, specializing in pre-clinical neuroscience drug discovery and neurotoxicity testing. The company leverages Microelectrode Array (MEA) technology combined with AI-driven analysis to conduct functional phenotypic screening using primary neuronal cultures and human iPSC-derived neurons. This approach enables the development of disease models, target validation, and compound profiling for central nervous system (CNS) disorders. As a private, pre-clinical stage company, NeuroProof serves as a key partner for pharmaceutical and biotech companies seeking to advance CNS drug candidates. With the growing demand for more predictive in vitro models and the rise of AI in drug discovery, NeuroProof is well-positioned to capture market share. However, the company faces competition from other CROs and in-house capabilities of large pharma. Its success hinges on maintaining technological leadership, expanding its client base, and securing repeat contracts. The company's long-standing presence since 2006 provides a solid foundation, but lack of public financial data limits detailed assessment.

Upcoming Catalysts (preview)

• H2 2026Major partnership with top pharmaceutical company for CNS drug screening40% success
• Q3 2026Launch of upgraded AI analytics platform for MEA data interpretation70% success
• Q4 2026Expansion of iPSC-derived neuron portfolio into new disease areas (e.g., ALS, Parkinson's)60% success